Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.

CONCLUSION: The current data support the value of adjunctive PER in child and adolescent patients with pharmacoresistant epilepsy in daily clinical practice. Perampanel was efficacious and generally well-tolerated as an add-on treatment for epilepsy. PMID: 30032806 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30032806?dopt=Abstract

Source: Epilepsy and Behaviour - July 24, 2018 Category: Neurology Authors: Lin KL, Lin JJ, Chou ML, Hung PC, Hsieh MY, Chou IJ, Lim SN, Wu T, Wang HS Tags: Epilepsy Behav Source Type: research